# CLEAR Outcomes (bempedoic acid in statin-intolerant people)

Study · id `cardio:clear-outcomes` · Cardiovascular Atlas · release `5dcd9b263fe17744` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: CLEAR Outcomes

Browse, condition area: Coronary and vascular disease  

## In plain language

A large trial of 13,970 people who could not or would not take statins because of side effects and who had, or were at high risk of, cardiovascular disease. Half took bempedoic acid, a daily pill, and half took placebo. Bempedoic acid lowered LDL cholesterol and the rate of a combined set of heart events, but the trial did not show an effect on death.

## Technical summary

Phase 3, randomized, double-blind, placebo-controlled trial (NCT02993406), 13,970 participants enrolled, started 2016-12-22 and primary completion 2022-11-07. The abstract reports the primary composite in 11.7% against 13.3% (hazard ratio 0.87, 95% CI 0.79 to 0.96), and no significant effects on fatal or nonfatal stroke, death from cardiovascular causes, or death from any cause. Funded by Esperion Therapeutics according to the paper; Esperion is the registry lead sponsor and the Cleveland Clinic a collaborator.

## Key facts

- Design: Allocation: randomized. Intervention model: parallel. Masking: triple. Primary purpose: treatment. (Registry values, in lower case.)
- Phase: Phase 3
- Enrolled: 13970 participants (enrolled count; Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo, snapshot `cardio:ctgov-nct02993406-2026-10-14`, retrieved 2026-10-14)
- Started: 2016-12-22 (actual) (Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo, snapshot `cardio:ctgov-nct02993406-2026-10-14`, retrieved 2026-10-14)
- Primary completion: 2022-11-07 (actual) (Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo, snapshot `cardio:ctgov-nct02993406-2026-10-14`, retrieved 2026-10-14)
- Completion: 2022-11-07 (actual) (Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo, snapshot `cardio:ctgov-nct02993406-2026-10-14`, retrieved 2026-10-14)
- Results first posted: 2024-01-03 (actual) (Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo, snapshot `cardio:ctgov-nct02993406-2026-10-14`, retrieved 2026-10-14)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; Colombia; Croatia; Czechia; Denmark; Estonia; Germany; Hungary; India; Latvia; Lithuania; Mexico; Netherlands; New Zealand; Poland; Romania; Russia; Serbia; Slovakia; South Africa; Spain; Ukraine; United Kingdom; Türkiye (Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo, snapshot `cardio:ctgov-nct02993406-2026-10-14`, retrieved 2026-10-14)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), snapshot `cardio:ctgov-nct02993406-2026-10-14`, retrieved 2026-10-14)

## Connected pages

- Tests bempedoic acid: Bempedoic acid (`cardio:bempedoic-acid`)

## Provenance

Content hash: cea35cae973208e60eb619f85ab4578010b61569c0fd2a132f62bafc39c9f915
Last substantive edit: 2026-10-14
Evidence last checked: 2026-10-14